Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer

NCT05141149 is registered in ClinicalTrials.gov with Prestige Biopharma Limited as lead sponsor.

NCT NCT05141149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05141149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First in Human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients With Advanced/Metastatic Pancreatic Cancer
Lead sponsor
Prestige Biopharma Limited
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 5, 2023
Completion date
December 31, 2026
Enrollment
80 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer